Prevalence, distress, management, and relief of pain during the last 3 months of cancer patients' life. Results of an Italian mortality follow-back survey.
about
A multicentre open-label safety and efficacy study of tetrodotoxin for cancer painInterleukin-6: an emerging regulator of pathological painCulture and end of life care: a scoping exercise in seven European countriesPain related to cancer treatments and diagnostic procedures: a no man's land?A Japanese region-wide survey of the knowledge, difficulties and self-reported palliative care practices among nurses.Preferred and actual place of death in haematological malignancy.Attributes of cancer patients admitted to the emergency department in one year.Prescription patterns of analgesics in the last 3 months of life: a retrospective analysis of 10202 lung cancer patientsThe effectiveness of the quality program Pac-IficO to improve pain management in hospitalized cancer patients: a before-after cluster phase II trial.Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain.Pain in underserved community-dwelling Chinese American cancer patients: demographic and medical correlates.Efficacy of an intrathecal multidrug infusion for pain control in older adults and in end-stage malignancies: A report of three cases.Variations in specialist palliative care referrals: findings from a population-based patient cohort of acute myeloid leukaemia, diffuse large B-cell lymphoma and myelomaCharacteristics and prognostic factors for pain management in 152 patients with lung cancer.Further Effort is Needed to Improve Management of Chronic Pain in Primary Care. Results from the Arkys ProjectBeyond Race and Gender: Measuring Behavioral and Social Indicators of Pain Treatment Satisfaction in Older Black and White Cancer Patients.Managing cancer pain at the end of life with multiple strong opioids: a population-based retrospective cohort study in primary care.Pain in malignant hematology.Cancer-related pain management: A review of knowledge and attitudes of healthcare professionals.A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics.Pain in blood cancers.Continuous deep sedation until death: palliation or physician-assisted death?Role of fosaprepitant, a neurokinin Type 1 receptor antagonist, in morphine-induced antinociception in ratsPhysicians' self-assessment of cancer pain treatment skills--more training required.The Liverpool Care Pathway for cancer patients dying in hospital medical wards: a before-after cluster phase II trial of outcomes reported by family members.Palliative care in patients with haematological neoplasms: An integrative systematic review.Measuring the quality of end-of-life care: Development, testing, and cultural validation of the Danish version of Views of Informal Carers' Evaluation of Services-Short Form.The influence of personality on reported pain and self-efficacy for pain management in older cancer patients.Symptoms and medication management in the end of life phase of high-grade glioma patients.Open questions in the treatment of cancer pain: time for a strong evidence-based approach?
P2860
Q24623970-640758CC-0B64-4A88-808E-67C91C26B33BQ26748646-32272FBB-9737-4E90-9615-3EF29F8D7BE3Q26830364-2F3D49CB-0A1E-44FB-8090-AD41AF2ECDB8Q27026749-BEFDDFA6-CBCE-4D7C-917E-05752DA6E1B0Q30363795-38966A6B-37E6-457E-9E57-F6EFC0761D7DQ33886101-0587DF26-2E95-4EB5-8293-F88FDADDC7D3Q34032373-C0110F6D-7858-490E-B83B-A76520C40D04Q35034598-DFA06DA0-E2A2-4B5D-9ED2-D0CC32FCAC53Q35134363-6B314D17-B56E-4BA1-AC0B-5C42BB9FF1C6Q35421746-A75B8809-9FBC-461C-BFC3-E6D3EE1B58B7Q35584570-6AA892D2-4516-4C1D-ABE3-D138A9CACCF9Q35659767-377F48D5-BC14-48BA-BCD3-36536E2A87C4Q36475705-E28EB08B-20A6-4DDB-AF76-785C76E576C9Q36833925-A77398BF-57ED-43C1-AFD2-FAA9B708E129Q37090319-98DC4D67-1ED5-499D-8F69-AFEC0B7F1785Q37429626-E8BDCF45-E9F5-4664-9A69-511B00CCA022Q37520551-A7D086EA-109F-4BD1-AE5C-7038CA7211A4Q37842353-86C777F5-15A0-4280-A851-553E22093871Q39057728-D23D97C8-478A-4560-8D75-43E7427513A5Q39217581-607015C2-1DE7-4D9A-9A43-74D560477E28Q39251577-6378CF61-B726-4FD2-AE98-C9B8693B39F5Q39294305-78F93674-F565-4EEE-BB7C-23AB30BE45B1Q41950284-7D8F92BA-EA91-46C3-BBBB-6E9E992EA337Q42635753-9A5FBF7F-C596-49EA-8BD7-A3BC5693F2C0Q44987748-7985B026-9EDF-4241-A3CB-313B90A6C836Q47609953-9ACA3D45-D755-4306-92CC-2B70316C6E2AQ47609982-C108DFFE-029F-40D6-A4EA-14F90B66A3D0Q48012336-8F08B531-067A-4043-BD3B-C42B4CC20DEAQ48588138-D5817883-9BF4-4F08-8D85-5955D92C58E0Q51036137-38C79EAE-BAC9-4EA5-ABF5-DB4788866661
P2860
Prevalence, distress, management, and relief of pain during the last 3 months of cancer patients' life. Results of an Italian mortality follow-back survey.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Prevalence, distress, manageme ...... mortality follow-back survey.
@en
Prevalence, distress, manageme ...... mortality follow-back survey.
@nl
type
label
Prevalence, distress, manageme ...... mortality follow-back survey.
@en
Prevalence, distress, manageme ...... mortality follow-back survey.
@nl
prefLabel
Prevalence, distress, manageme ...... mortality follow-back survey.
@en
Prevalence, distress, manageme ...... mortality follow-back survey.
@nl
P2093
P2860
P921
P356
P1433
P1476
Prevalence, distress, manageme ...... n mortality follow-back survey
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDN700
P577
2009-01-22T00:00:00Z